nature’s lead in antimicrobials


Antibiotic resistance is a major health threat worldwide. An existing problem only set to worsen, addressing this crisis of modern medicine is a now a global imperative.

Nylexa™ is one potential solution to the worsening antibiotic resistance crisis and a strategy that could be introduced into clinical practice within a much shorter timescale than any new antibiotic(s) developed from first principle. 

Derived from the same aminothiol platform as Lynovex®, Nylexa™ is an antibiotic potentiator/resistance breaking agent being developed as a parenterally administered adjunct to a number of antibiotic classes; extending their utility and scope against drug resistant, even MDR and XDR bacterial infections. Put simply, when used alongside certain existing antibiotics against drug resistant bacterial pathogens, Nylexa™ allows that antibiotic to work again or work better than it did before, both in terms of potency (dose required) and spectrum of activity. Nylexa™ is antibiotic in its own right but is intended primarily as an adjunct agent. 

Importantly, resistance breakers such as Nylexa™ have a faster route to clinic than antibiotic NCEs and as a repurposed aminothiol, Nylexa's development could be further expedited on the basis of existing clinical data in other indications. In vitro and in vivo data generated thus far have demonstrated Nylexa’s efficacy in a number of infection models, supported by Lynovex® clinical data.



We must increase the supply of new antimicrobials effective ​against drug-resistant drugs

Key antibiotic facts:

Review on Antimicrobial Resistance report, 19 May 2016 - key findings

  • 700,000 deaths (current rate) globally every year are attributed to antimicrobial resistance (AMR).
  • By 2050, the death rate could be as high as 10 million per year – that’s one person every 3 seconds.
  • Development of new drugs and improvement of existing ones is key in the fight against AMR
  • By 2050, the cost of AMR could be as high as $100 trillion meaning every person alive in the world today will be $10,000 worse off.
  • The estimated cost of global action to fight AMR is estimated to be $40 billion over a 10 year period.
  • In the US alone, there are more than 2 million infections per year, costing the US Healthcare system in excess of $20 billion per year.
  • During the ‘golden era’ of antibiotic discovery in the 1940s and 1950s saw a steady stream of products coming to market, today’s total antibiotics pipeline is fewer than 50.
  • Between 2003 - 2013, less than 5% of VC investment in pharmaceutical R&D was for antimicrobial development.